期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

索拉非尼联合化疗治疗FLT3-ITD突变阳性急性髓系白血病九例报告并文献复习 被引量：10

Sorafenib in combination with chemotherapy as induction therapy for FLT3-ITD positive acute myeloid leukemia： nine cases report and literatures review
原文传递
导出
摘要 索拉非尼（sorafenib）是一种小分子多激酶抑制剂,可以抑制FMS样酪氨酸激酶3（FLT3）、c-kit、RAS/RAF/MEK/ERK信号通路、血管内皮生长因子受体（VEGFR）、血小板衍生的生长因子受体（PDGFR）、成纤维细胞生长因子受体（FGFR）等[1],从而成为新型的靶向急性髓系白血病（AML）治疗药物.关于索拉非尼治疗FLT3-ITD突变阳性AML的疗效,国外已有系统的研究,国内仅有个案报道[2-4].现将我们应用索拉非尼联合化疗治疗9例FLT3-ITD突变阳性AML患者的结果报告如下并进行相关文献复习.
作者 刘莎 魏旭东 尹青松 米瑞华 张龑莉 汪萍 艾昊 赵慧芳 韩利杰
机构地区 郑州大学附属肿瘤医院、河南省肿瘤医院血液科
出处 《中华血液学杂志》 CAS CSCD 北大核心 2015年第3期241-244,共4页 Chinese Journal of Hematology
基金 国家自然科学基金（81170520）
关键词 急性髓系白血病 索拉非尼 治疗药物 文献复习 联合化疗 血管内皮生长因子受体 阳性 突变
分类号 R733.71 [医药卫生—肿瘤]
  • 相关文献

参考文献4

二级参考文献38

  • 1王莉红,周春林,张新伟,陈森,王敏,王建祥.FLT3基因内部串联重复突变与急性白血病的关系及临床意义[J].中华血液学杂志,2004,25(7):393-396. 被引量：35
  • 2Lowinger TB,Riedl B,Dumas J,et al.Design and discovery of small molecules targeting raf-1 kinase.Curr Pharm Des,2002,8:2269-2278.
  • 3Hayakawa F,Towatari M,Kiyoi H,et al.Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines.Oncogene,2000,19:624-631.
  • 4Levis M,Pham R,Smith BD,et al.In vitro studies of a FLT3 inhibitor combined with chemotherapy:sequence of administration is important to achieve synergistic cytotoxic effects.Blood,2004,104:1145-1150.
  • 5Mori S,Cortes J,Kantarjian H,et al.Potential role of sorafenib in the treatment of acute myeloid leukemia.Leuk Lymphoma,2008,49:2246-2255.
  • 6Kelly LM,Yu JC,Boulton CL,et al.CT 3518,a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).Cancer Cell,2002,1:421-432.
  • 7Stone RM,DeAngelo DJ,Klimek V,et al.Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor,PKC412.Blood,2005,105:54-60.
  • 8DeAngelo DJ,Stone RM,Heaney ML,et al.Phase 1 clinical results with tandutinib (MLN518),a novel FLT3 antagonist,in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome:safety,pharmacokinetics,and pharmacodynamics.Blood,2006,108:3674-3681.
  • 9Knapper S,Burnett AK,Littlewood T,et al.A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701)as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy.Blood,2006,108:3262-3270.
  • 10Wilhelm SM,Carter C,Tang L,et al.BAY43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.Cancer Res,2004,64:7099-7109.

共引文献8

同被引文献53

  • 1黄河,曹伟杰.血液系统恶性疾病靶向治疗的研究进展[J].浙江大学学报（医学版）,2007,36(4):313-318. 被引量：5
  • 2Safaian NN, Czibere A, Bruns 1, et al. Sorafenib (Ncxavar) induces moleeular remission arid regressiorl of extramedullary disease in a patient with FLT3-ITD + acute myeloid leukemia[ J ]. Leuk Res, 2009,33 (2) : 348-350.
  • 3Man CH, Fung TK, Ho C, et al. Sorafcnib treatment of FH3- ITD( + ) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation [ J ]. Blood, 2012,119 ( 22 ) : 5133- 5143.
  • 4Mori S, Cortes J, Kantarjian H, et al. Potential role of soratenib in the treatment of acute myeloid leukemia[ J]. Iuk I,ymphoma, 2008,49 ( 12 ) :2246-2255.
  • 5Hu B, Vikas P, Mohty M, et al. Allogeneie stem cell transplantation and targeted therapy tbr FLT3/ITI) + acute myeloid leukemia: an update [ J ]. Expert Rev Hematol, 2014,7 (2) :301-315.
  • 6Zhang W, Konopleva M, Shi YX, et al. Mutant FLT3: a direcl target of sorafenib in acute myelogenous leukemia [ J ]. J Natl Cancer lnst, 2008, 100 ( 3 ) : 184-198.
  • 7Metzelder S, Wang Y, Wollmer E, el al. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allugeneie stem cell transplantation[ J ]. Blood, 2009,113 (26) :6567-6571.
  • 8Metzelder SK, Schroeder T, Finck A, et al. tligh aclivity ot sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses [ J ]. Leukemia, 2012,26 ( 11 ) :2353-2359.
  • 9Yokoyama H, Lundqvist A, Su S, et al. Toxic effec:ts of soralenih when given early 'after allogeneie hematopoietie stem eel] transplantation[ J ]. Blood, 2010, 116 ( 15 ) : 2858-2859.
  • 10刘涛,刘珍珍,朱平,程克棣,Lars Ronnstrand.FLT3在急性白血病靶向治疗中的研究进展[J].中国药理学通报,2008,24(12):1545-1548. 被引量：4

引证文献10

二级引证文献24

中华血液学杂志
2015年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部